Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 18, 2026, 9:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: KLH Clear all
Completed Phase 2 Interventional

Study of Immune Responses and Safety of Recombinant Human CD40 Ligand in Patients With X-Linked Hyper-IgM Syndrome

NCT00001145
View directory record Official record
Conditions
Immunoproliferative Disorder
Interventions
Bacteriophage, rhuCD40L, KLH
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 18, 2026, 9:07 AM EDT
Completed Phase 1 Interventional

Autologous Dendritic Cells Pulsed With Autologous Apoptotic Tumor Cells Administered to Patients With Brain Tumors

NCT00893945
View directory record Official record
Conditions
Brain Tumors
Interventions
DC/AAT, DC/AAT-Flu, DC/KLH
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 22, 2014 · Synced Sep 18, 2026, 9:07 AM EDT
Completed Phase 1 Interventional

Phase 1 Study of Anti-OX40 in Patients With Advanced Cancer

NCT01644968
View directory record Official record
Conditions
Advanced Cancer
Interventions
Cohort 1 anti-OX40, Cohort 2 anti-OX40, Cohort 3 anti-OX40, Tetanus Day 29, Tetanus Day 1, KLH Day 1, KLH Day 29
Drug · Biological
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2017
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 16, 2022 · Synced Sep 18, 2026, 9:07 AM EDT
Completed Not applicable Interventional Results available

Vaccine Therapy in Treating Patients at High Risk for Breast Cancer Recurrence

NCT00030823
View directory record Official record
Conditions
Breast Cancer
Interventions
Globo-H-GM2-Lewis-y-MUC1-32(aa)-sTn(c)-TF(c)-Tn(c)-KLH conjugate vaccine, QS21
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 29, 2015 · Synced Sep 18, 2026, 9:07 AM EDT
Completed Not applicable Interventional

Administration of Growth Hormone to Increase CD4+ Count in Patients Taking Anti-HIV Drugs

NCT00050921
View directory record Official record
Conditions
HIV Infections
Interventions
somatropin, Hepatitis A virus, inactivated, Keyhole-Limpet Hemocyanin
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
13
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 18, 2026, 9:07 AM EDT
Terminated Early Phase 1 Interventional

Vaccine Therapy in Treating Patients With Acute Lymphoblastic Leukemia

NCT00020670
View directory record Official record
Conditions
Leukemia
Interventions
CD 40
Biological
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
Not listed
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 19, 2017 · Synced Sep 18, 2026, 9:07 AM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Breast Cancer

NCT00004156
View directory record Official record
Conditions
Breast Cancer
Interventions
MUC1-KLH vaccine/QS21
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 29, 2013 · Synced Sep 18, 2026, 9:07 AM EDT
Terminated Phase 2 Interventional

Vaccine Therapy and GM-CSF in Treating Patients With Progressive Non-Hodgkin's Lymphoma

NCT00104819
View directory record Official record
Conditions
Lymphoma
Interventions
autologous immunoglobulin idiotype-KLH conjugate vaccine, sargramostim
Biological
Lead sponsor
Favrille
Industry
Eligibility
18 Years and older
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
51
States / cities
Birmingham, Alabama • Beverly Hills, California • La Jolla, California + 43 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2013 · Synced Sep 18, 2026, 9:07 AM EDT
Completed Phase 1 Interventional

Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma

NCT01250470
View directory record Official record
Conditions
Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Giant Cell Glioblastoma, Glioblastoma, Gliosarcoma, Mixed Glioma, Recurrent Brain Neoplasm
Interventions
Laboratory Biomarker Analysis, Montanide ISA-51/Survivin Peptide Vaccine, Sargramostim
Other · Drug · Biological
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 26, 2017 · Synced Sep 18, 2026, 9:07 AM EDT
Completed Not applicable Interventional Results available

Vaccine Therapy and QS21 in Treating Patients With Metastatic Breast Cancer

NCT00470574
View directory record Official record
Conditions
Breast Cancer
Interventions
QS21, sialyl Lewisª-keyhole limpet hemocyanin conjugate vaccine, immunoenzyme technique, immunologic technique, laboratory biomarker analysis
Biological · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Sep 18, 2026, 9:07 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Trial of ID-Specific Donor Vaccinated Lymphocyte Infusion for Patients With Myeloma Relapsing or Failing to Achieve a Complete Remission After an Allogenic Transplant

NCT01174082
View directory record Official record
Conditions
Myeloma
Interventions
KLH Vaccine, KLH-id Vaccine, GM-CSF, Apheresis, Donor Lymphocyte Infusion (DLI)
Biological · Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 31, 2018 · Synced Sep 18, 2026, 9:07 AM EDT
Withdrawn Phase 2 Interventional

Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma

NCT00621036
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Lymphoma, Lymphoproliferative Disorder, Small Intestine Cancer
Interventions
autologous immunoglobulin idiotype-KLH conjugate vaccine, sargramostim, methotrexate, thiotepa, radiation therapy
Biological · Drug · Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 25, 2018 · Synced Sep 18, 2026, 9:07 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Dendritic Cell Vaccine Study (DC/PC3) for Prostate Cancer

NCT00345293
View directory record Official record
Conditions
Prostate Cancer
Interventions
autologous dendritic cell vaccine (DC/PC3)
Biological
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years and older · Male only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 17, 2016 · Synced Sep 18, 2026, 9:07 AM EDT
Completed Phase 1 Interventional

Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines

NCT00001512
View directory record Official record
Conditions
B Cell Lymphoma, Follicular Lymphoma, Lymphoma
Interventions
Id-KLH Vaccine, GM-CSF
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 18, 2026, 9:07 AM EDT
Completed Phase 2 Interventional

Vaccine Therapy in Treating Patients With Multiple Myeloma

NCT00019097
View directory record Official record
Conditions
Stage II Multiple Myeloma, Stage III Multiple Myeloma, Refractory Plasma Cell Neoplasm
Interventions
autologous tumor cell vaccine, keyhole limpet hemocyanin, melphalan, sargramostim
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Timeline
1995 – 2007
U.S. locations
3
States / cities
Little Rock, Arkansas • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2024 · Synced Sep 18, 2026, 9:07 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Effectiveness of a Vaccine for Prostate Cancer That Uses Each Patients' Own Immune Cells.

NCT00289341
View directory record Official record
Conditions
Prostate Cancer
Interventions
vaccine vehicle only, DC/LNCaP
Biological
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years and older · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 17, 2013 · Synced Sep 18, 2026, 9:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Responses to Immunization With Keyhole Limpet Hemocyanin Administered by Scarification and the Intradermal Route

NCT00614731
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
KLH carrier-protein
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Sep 18, 2026, 9:07 AM EDT
Completed Phase 2 Interventional

Vaccine Therapy and Sargramostim After Rituximab in Treating Patients With Refractory or Progressive Non-Hodgkin's Lymphoma

NCT00071955
View directory record Official record
Conditions
Lymphoma
Interventions
autologous immunoglobulin idiotype-KLH conjugate vaccine, sargramostim
Biological
Lead sponsor
Genitope Corporation
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
9
States / cities
Stanford, California • Chicago, Illinois • Indianapolis, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Sep 18, 2026, 9:07 AM EDT
Not listed Phase 2 Interventional

Rituximab, Vaccine Therapy, and GM-CSF in Treating Patients With Non-Hodgkin's Lymphoma

NCT00258336
View directory record Official record
Conditions
Lymphoma
Interventions
autologous immunoglobulin idiotype-KLH conjugate vaccine, rituximab, sargramostim
Biological
Lead sponsor
Favrille
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 9, 2014 · Synced Sep 18, 2026, 9:07 AM EDT
Active, not recruiting Phase 1 Interventional

SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy

NCT02334865
View directory record Official record
Conditions
Partial Response of Multiple Myeloma or Plasma Cell Leukemia, Plasma Cell Myeloma
Interventions
Incomplete Freund's Adjuvant, Laboratory Biomarker Analysis, Lenalidomide, Sargramostim, SVN53-67/M57-KLH Peptide Vaccine
Biological · Other · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
2
States / cities
Buffalo, New York • Rochester, New York
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Sep 18, 2026, 9:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous and Subcutaneous Single and Repeated Doses of SAR441344 in Healthy Adult Subjects

NCT05845996
View directory record Official record
Conditions
Healthy Volunteers
Interventions
SAR441344, placebo, Keyhole limpet hemocyanin
Drug · Biological
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 45 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Sep 18, 2026, 9:07 AM EDT
Completed Phase 1 Interventional

Vaccine Therapy Plus QS21 in Treating Women With Breast Cancer Who Have No Evidence of Disease

NCT00003357
View directory record Official record
Conditions
Breast Cancer
Interventions
GM2-KLH vaccine, QS21
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 12, 2012 · Synced Sep 18, 2026, 9:07 AM EDT
Completed Phase 1 Interventional

Vaccination of Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype

NCT00001572
View directory record Official record
Conditions
B Cell Lymphoma, Follicular Lymphoma, Neoplasm
Interventions
Id-KLH Vaccine, QS-21 (Stimulation-QS-21) Drug
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 18, 2026, 9:07 AM EDT
Completed Phase 1 Interventional

Vaccination of Prostate Cancer Patients With MUC-2-KLH Conjugate Plus the Immunological Adjuvant QS21

NCT00698711
View directory record Official record
Conditions
Prostate Cancer
Interventions
MUC-2-KLH
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 30, 2012 · Synced Sep 18, 2026, 9:07 AM EDT